You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Photoacoustic CT for Preclinical Molecular Imaging

    SBC: OPTOSONICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this collaborative research project is to commercialize a prototype photoacoustic computed-tomography (PCT) scanner for conducting preclinical molecular imaging. This scanner has been developed by OptoSonics with funding from a Fast Track SBIR grant from the National Cancer Institute (R44-CA-102891) and additional private funding fro ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Predicting DILI liability by transcription factor profiling

    SBC: ATTAGENE, INC.            Topic: 400

    PROJECT SUMMARYDrug induced liver injuryDILIis the main reason for drug attrition during development and a leading cause of post market drug withdrawalHerewe propose a systems biology approach to detect drug candidates with DILI liabilities at early stages of developmentThis approach is based on the assessment of drug induced perturbations of multiple signal transduction pathways in hepatocytic ce ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting the checkpoint regulator VISTA for treatment of inflammatory disease

    SBC: Immunext, Inc.            Topic: R

    ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibodymAbthat we aim to bring to the clinic for the treatment of human autoimmune diseaseVISTA is a member of the highly successful negative checkpoint regulatorNCRfamily of drug targetswhose members have demonstrated proven efficacy in inducing long term remissions in human cancersWe contend that antibodies that suppres ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung Disease

    SBC: POLAREAN, INC.            Topic: NHLBI

    PROJECT SUMMARYABSTRACT Chronic respiratory diseasessuch as COPDasthmaand cystic fibrosisCFare therd leading cause of death in the USwith costs exceeding $B yearA major obstacle to evaluate therapies for these diseases is that currently available tools to assess lung function are either insensitive to early disease or unsuitable for longitudinal useThough ubiquitouspulmonary function testing via s ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Discovering a Disease Modifying Therapeutic to Treat Huntington's Disease

    SBC: CHAPERONE THERAPEUTICS, INC.            Topic: NIA

    Protein misfolding and aggregationleading to chronic inflammationsynaptic dysfunction and neuronal death are common hallmarks of neurodegenerative diseases including Alzheimer s diseaseADand Huntington s diseaseHDWhile overmillion Americans suffer from ADand oversuffer from HDcurrent therapies target symptoms but not the underlying pathophysiology of protein misfoldingaggregation and its downstrea ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a mobile and automated platform for multiplexed multi-modality imaging

    SBC: Sonovol, Inc.            Topic: 102

    Abstract Bioluminescence imagingBLIsystems are installed in thousands of facilities and labsand with their straightforward and low cost workflow for longitudinal studiesare the most commonly used preclinical modality for assessing tumor models in rodentsThere currently is no high throughput and low cost system enabling BLI images to be combined with anatomical images of soft tissue to confirm tumo ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Clinical evaluation of the novel, uni-directional, Pd-103 CivaSheet for Pancreatic Cancers

    SBC: CIVATECH ONCOLOGY INC            Topic: 102

    CivaTech Oncology s mission is to provide improved radiation therapy directly to localized tumorsThe Company has developed a novelpolymer encapsulatedmembrane like radiation source that emits radiation on only one side of the devicethe CivaSheetThis directional source is compatible with open and minimally invasive surgical techniques and has FDA clearance to be used as primary or combined cancer t ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Breast Cancer Locator

    SBC: CAIRNSURGICAL, INC.            Topic: 101

    PROJECT SUMMARY ABSTRACTCairnSurgical LLCa Dartmouth spin off companywill optimize and test multi site clinical feasibility of a new image guided intervention devicethe Breast Cancer LocatorBCLin breast conserving surgeryBCStoieliminate wire localizationa moderately effectivesomewhat costly and certainly inconvenient procedure for patients and surgeonsand concomitantly toiireduce positive margin r ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel technologies for detection of podocytes from preeclamptic patients

    SBC: AFFINERGY, LLC            Topic: NICHD

    Preeclampsia is a complication of pregnancy characterized by elevated blood pressureproteinuriaand endothelial dysfunction involving multiple organ systemsWorldwidepreeclampsia is the largest cause of fetal and maternal morbidity and mortalityand accounts for nearlyof maternal deaths in the United States alone each yearCurrentlythere is no approved diagnostic test to predict which patients will de ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of GIFT4: a B cell focused immunotherapy for cancer

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    Project Summary Our goal is to develop a novel immunotherapy for the treatment of melanomaand potentially a wide array of tumorsAlthough surveillance by the immune system eliminates cancer cells in some instancestumor cells have developed a variety of mechanisms to escape immune recognition often resulting in tumor outgrowthImmune checkpoint inhibitorse gipilimumabnivolumaband pembrolizumaband cel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government